Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 18;10(5):801. doi: 10.3390/vaccines10050801

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Neutralizing activity against the SARS-CoV-2 wild-type (G614), United Kingdom (UK), and South African (SA) variants. (Panel A) The analysis included 5 controls (-ctrl- 3 with previous COVID-19 –exC-), 5 ex-C patients (of which 2 were treated with mycophenolate mofetil (MFM) at 3 g/day, 2 with baricitinib at 4 mg/day, and 1 with methotrexate at 15 mg/week), and 12 COVID-naïve patients (naïve pt), of which 2 treated with MFM at 3 g/day, 2 with baricitinib at 4 mg/day, 2 with methotrexate at 15 mg/week, 2 with secukinumab at 150 mg/4 weeks, and 4 with adalimumab at 40 mg/2 weeks. (Panel B) Data are shown for the patients treated with MFM versus other immunosuppressants (other IS). Each black spot represents a patient, the bars indicate means and standard errors of the mean (SEM) of the percentages of cytopathic effect compared to the positive infection control.